Skip to content

GANX

Gain Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.80
−1.10%
Ask drillr
0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+7.1%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Jul 17, 2026Riley Jeffrey Scott · directorA-Award25,000$1.68
Jul 17, 2026HASLER HANS PETER · directorA-Award25,000$1.68
Jul 17, 2026Melincoff Gwen A · directorA-Award25,000$1.68
Jul 17, 2026GOLDSTEIN DOV A MD · directorA-Award25,000$1.68
Jul 17, 2026Islam Khalid · directorA-Award25,000$1.68
Jul 17, 2026Nicaise Claude · directorA-Award25,000$1.68
Mar 26, 2026Fuggetta Gianluca · officer: See RemarkA-Award50,000$1.86
Mar 26, 2026Mack Gene · director, officer: CEO, PresidentA-Award200,000$1.86
Jun 25, 2025Nicaise Claude · directorA-Award15,000$1.79
Jun 25, 2025GOLDSTEIN DOV A MD · directorA-Award15,000$1.79
Jun 25, 2025Melincoff Gwen A · directorA-Award15,000$1.79
Jun 25, 2025Islam Khalid · directorA-Award15,000$1.79
Jun 25, 2025Riley Jeffrey Scott · directorA-Award15,000$1.79
Jun 25, 2025RICHMAN ERIC I · directorA-Award15,000$1.79
Jun 25, 2025HASLER HANS PETER · directorA-Award15,000$1.79
Mar 21, 2025Fuggetta Gianluca · officer: See RemarkA-Award50,000$2.29
Mar 21, 2025Mack Gene · director, officer: CEO, PresidentA-Award200,000$2.29
Jan 7, 2025Mack Gene · director, officer: CEO, PresidentA-Award271,325$2.44
Aug 12, 2024Mack Gene · officer: CFO and Interim CEOPurchase14,400$1.01
Aug 12, 2024Islam Khalid · director, officer: Executive ChairmanPurchase50,000$1.00
Jul 1, 2024RICHMAN ERIC I · directorPurchase12,000$1.21
Jul 1, 2024RICHMAN ERIC I · directorPurchase5,000$1.23
Jun 26, 2024Islam Khalid · directorA-Award15,000$1.29
Jun 26, 2024HASLER HANS PETER · directorA-Award15,000$1.29
Jun 26, 2024Nicaise Claude · directorA-Award15,000$1.29
Jun 26, 2024RICHMAN ERIC I · directorA-Award15,000$1.29
Jun 26, 2024GOLDSTEIN DOV A MD · directorA-Award15,000$1.29
Jun 26, 2024Riley Jeffrey Scott · directorA-Award15,000$1.29
Jun 26, 2024Melincoff Gwen A · directorA-Award15,000$1.29
Apr 8, 2024Mack Gene · officer: Chief Financial OfficerA-Award200,000$3.56
Institutional positioning

13F filings over the trailing two quarters

New 10Increased 11Reduced 10Sold out 43
FilerActionSharesFiled
MARSHALL WACE, LLPIncreased1,769,788May 15, 2026
POTOMAC CAPITAL MANAGEMENT, INC.Reduced1,008,600May 14, 2026
JONES FINANCIAL COMPANIES LLLPReduced631,615May 15, 2026
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.Unchanged568,645Apr 30, 2026
DME CAPITAL MANAGEMENT, LPUnchanged566,130May 15, 2026
SUSQUEHANNA INTERNATIONAL GROUP, LLPReduced469,567May 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased447,342May 15, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position399,886May 15, 2026
GSA CAPITAL PARTNERS LLPIncreased312,467May 8, 2026
JANE STREET GROUP, LLCIncreased255,483May 12, 2026
VANGUARD FIDUCIARY TRUST CONew Position229,979May 8, 2026
BLACKROCK, INC.Increased225,046May 13, 2026
UBS GROUP AGIncreased220,489May 5, 2026
CITADEL ADVISORS LLCIncreased195,224Sep 2, 2026
CRESSET ASSET MANAGEMENT, LLCUnchanged160,000May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 17, 2026